A RANDOMISED PLACEBO-CONTROLLED CLINICAL TRIAL OF CURCUMA LONGA EXTRACT FOR TREATING SYMPTOMS AND EFFUSION-SYNOVITIS OF KNEE OSTEOARTHRITIS (CURKOA TRIAL)

B. Antony1, 2, Z. Wang1, T. Winzenberg1, G. Cai1, L. Laslett1, D. Aitken1, I. Hopper1, A. Singh1, R. Jones3, J. Fripp4, C. Ding5, G. Jones6, 1University of Tasmania, Menzies Institute for Medical Research, Hobart, Australia; 2Monash University, Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Melbourne, Australia; 3Royal Hobart Hospital, Department of Radiology, Hobart, Australia; 4University of Queensland, Biomedical Informatics & Imaging Group, CSIRO Health and Biosecurity, The Australian e-Health Research Centre, Brisbane, Australia

Methods: In this randomised, double-blind, placebo-controlled trial, participants with significant knee pain (≥ 40 mm on a 100-mm visual analog scale [VAS]), symptomatic knee OA (by ACR criteria) and ultrasound defined effusion-synovitis were randomised to receive Curcuma longa extract (80% aqueous based extract standardized to turmerosaccharides + 20% curcuminoids, 2 x 500 mg capsules/day) or identical placebo for 12 weeks. Knee MRI scans were obtained at baseline and 12 weeks. Coprimary outcomes were changes in knee pain assessed by VAS and change in knee effusion-synovitis volume assessed by MRI over 12 weeks.

Results: Among 70 participants (36 received Curcuma longa, 34 received placebo, age 61.8±8.6 years, 56% female), Curcuma longa significantly improved VAS knee pain compared to placebo (-9.1±1.9 mm, 95% confidence interval [CI] [-17.9 to -0.4]) over 12 weeks, equivalent to a standardised effect size of 0.50. There was no significant difference in group change in ultrasound-defined effusion-synovitis volume (3.2±4.3 mL [-0.33, 6.82]). There were significantly greater reductions in WOMAC knee pain (-47.2±22.7 mm [-81.2, -13.2]), WOMAC function (-112.3±79.4 mm [-222.7, -17.4]) and significantly more OARSI-OMERACT treatment responders (63% treatment vs. 38% placebo) in the Curcuma longa group compared to the placebo group. There was no significant between-group difference in lateral femoral cartilage T2 relaxation time (-0.38 [-222.79 to -1.74]) and significantly more OARSI-OMERACT treatment responders (63% treatment vs. 38% placebo) in the Curcuma longa group compared to the placebo group. There was no significant between-group difference in lateral femoral cartilage T2 relaxation time (-0.38 [10.10 to 0.34]) assessed from compositional MRI. The incidence of adverse events was similar in the Curcuma longa (n=14 (39%)) and placebo (n=16 (53%)) groups over 12 weeks (P=0.24).

Conclusion: An extract of Curcuma longa significantly improved knee pain in an inflammatory phenotype of knee OA patients over 12 weeks compared to placebo but had no effect on knee effusion-synovitis and cartilage composition assessed using MRI. The moderate effect size of the treatment supports the use of Curcuma longa extract for the symptomatic management of knee OA.

Background: Pharmacological therapies are limited, associated with off-target effects, are frequently contraindicated, and only modestly effective for pain in osteoarthrisis (OA). Effusion and synovitis are common in OA and are associated with symptomatic and structural progression of OA. Curcuma longa (Turmeric) extract has anti-inflammatory effects and is gaining popularity in the treatment of OA despite the lack of high-quality evidence.

Objectives: The CurKOA trial aimed to determine the efficacy of Curcuma longa extract for reducing knee symptoms and effusion-synovitis in patients with symptomatic knee OA and knee effusion-synovitis.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.5139